Business
Kezar Announces Presentations During Upcoming Scientific Conferences
SOUTH SAN FRANCISCO, Calif., May 20, 2020 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and
About this update from Kezar Life Sciences, Inc.
[{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., May 20, 2020 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmune disease and cancer, today announced presentations during upcoming major scientific conferences.\n “Kezar’s unique ability to translate novel science into viable treatment options is underscored by the selection of three abstracts featuring data from both of our programs targeting protein homeostasis,” said Christopher Kirk, PhD, Kezar’s President and Chief Scientific Officer. “The acceptance of a pre-clinical abstract to ASCO serves as a testament to the innovative mechanism and potential of KZR-261 to target a number of solid and liquid tumor types. Furthermore, the growing body of clinical data demonstrating the broad immunomodulatory effects of KZR-616 supports its potential to treat a wide range of severe autoimmune diseases.” Following is an overview of Kezar’s upcoming scientific presentations, which will also be made available on the Company’s website: American Society of Clinical Oncology (ASCO20 Virtual) Title: Preclinical evaluation of KZR-261, a novel small molecule inhibitor of Sec61Abstract N°: 3582 (poster presentation)Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor BiologyAuthors: Eric Lowe, R. Andrea Fan, Jing Jiang, Henry W.B. Johnson, Christopher J. Kirk, Dustin McMinn, Beatriz Millare, Tony Muchamuel, Yu Qian, Brian Tuch, Jennifer A. Whang, Patricia ZunoDate: Available beginning May 29, 2020, 8:00 AM ET European League Against Rheumatism (EULAR 2020 E-Congress) Title: Treatment of SLE with the Immunoproteasome Inhibitor KZR-616: Results from the First 4 Cohorts of the MISSION Study, an Open-Label Phase 1b Dose Escalation TrialAbstract N°: AB0373 (abstract publication)Session: SLE, Sjögren’s and APS - treatmentAuthors: Richard Furie, S.V. Parikh, Adonis Maiquez, Amber Khan, Orlando Moreno, Miguel Soneira, Christopher Kirk, Darrin Bomba, Ken Harvey, Mary Katherine FarmerDate: Additional data available on June 3, 2020 on Kezar’s corporate website 25th Annual European Hematology Association (EHA25 Virtual) Title: Selective Immunoproteasome Inhibitor, KZR-616, A Novel Therapy for Autoimmune Hemolytic Anemia and Immune Thrombocytopenia: Biomarker Activity a...